Paul Benson
Overview
Explore the profile of Paul Benson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moyle G, Gruber J, Dunbar M, Radtchenko J, Frick A, Marongiu A, et al.
AIDS
. 2025 Mar;
PMID: 40053475
Objective: Treatment adherence remains critical in maintaining HIV RNA suppression on antiretroviral therapy. High genetic barrier regimens constructed with three long half-life agents may prevent resistance emergence and can be...
2.
Brar I, Ruane P, Berhe M, Brinson C, Benson P, Henry K, et al.
Medicine (Baltimore)
. 2025 Feb;
104(8):e41482.
PMID: 39993074
Background: The phase 3 randomized, active-controlled GS-US-380-1844 (NCT02603120) study evaluated switching to the single-tablet regimen bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) from dolutegravir (DTG), abacavir (ABC), and lamivudine (3TC) among...
3.
Saleh A, Hyder S, Hasnie U, Chung E, Benson P, Prime D, et al.
JACC Case Rep
. 2024 Dec;
29(23):102793.
PMID: 39691325
Embolic myocardial infarction (MI) due to malignancy is a rare clinical entity defined by embolization of cancerous tissue to the coronary arteries. We present the case of a 49-year-old man...
4.
Kelley C, Acevedo-Quinones M, Agwu A, Avihingsanon A, Benson P, Blumenthal J, et al.
N Engl J Med
. 2024 Nov;
PMID: 39602624
Background: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender...
5.
Benson P, Kuretski J, Donovan C, Harper G, Merrill D, Metzner A, et al.
Infect Dis Ther
. 2024 Apr;
13(4):875-889.
PMID: 38570444
Introduction: Dolutegravir/lamivudine (DTG/3TC) was first approved by the US Food and Drug Administration in 2019 for the treatment of antiretroviral therapy (ART)-naive people with HIV-1 based on results from the...
6.
Schneider S, Blick G, Burke C, Ward D, Benson P, Felizarta F, et al.
Infect Dis Ther
. 2024 Apr;
13(4):891-906.
PMID: 38570443
Introduction: Dolutegravir/lamivudine (DTG/3TC) and dolutegravir/rilpivirine (DTG/RPV) are fixed-dose, complete, single-tablet, two-drug regimens (2DRs) indicated for HIV-1. DTG/3TC is approved for antiretroviral therapy (ART)-naive people with HIV-1 and virologically suppressed individuals...
7.
Riegler A, Benson P, Long K, Leal Jr S
Cell Death Discov
. 2023 Nov;
9(1):420.
PMID: 37985756
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes severe lower airway disease and death in a subset of patients. Knowledge on the relative contribution of programmed cell death (PCD) to...
8.
Riegler A, Benson P, Long K, Leal S
Res Sq
. 2023 Jul;
PMID: 37461686
SARS-CoV-2 (SARS-2) causes severe lower airway disease and death in a subset of patients. Knowledge on the relative contribution of programmed cell death (PCD) to lung pathology is limited to...
9.
Sharma N, Patel K, Sari E, Shankar S, Gastanadui M, Moncada-Giraldo D, et al.
J Clin Invest
. 2023 Jun;
133(16).
PMID: 37384419
No abstract available.
10.
Margaroli C, Benson P, Gastanadui M, Song C, Viera L, Xing D, et al.
Front Med (Lausanne)
. 2023 Mar;
10:1118024.
PMID: 36968839
Objectives: Our objective was to examine coronary endothelial and myocardial programming in patients with severe COVID-19 utilizing digital spatial transcriptomics. Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has well-established links...